19.96%SPY 79.52 
5.39%XLF 9.68 3.09%
Digg
Del.icio.us
Newsvine 
Facebook
Stumbleupon
INDIANAPOLIS - Drug developer Eli Lilly and Co. said Thursday it asked the Food and Drug Administration to approve its depression drug Cymbalta as a chronic pain treatment.
| LLY | 30.43 |  0.52 |
The company said its filing with the FDA is based on studies conducted in patients with chronic osteoarthritis pain of the knee and chronic low back pain. The company also used studies focusing on diabetic peripheral neuropathic pain, or nerve damage caused by diabetes, and the pain disorder fibromyalgia.
During the first quarter, Cymbalta sales rose 37 percent to $605 million.
Six companies in the financial-services sector are being added to the Russell 1000 in this year's reconstitution of the large stock index, wh...
As more Americans rely on charity amid worsening economic gloom, operators of fo...
The 32 American students chosen as Rhodes Scholars for 2009, listed by geographic region: District I:
Split Big Profits! You Find it & We Fund it! Co-Own Or Cash Out! Get Free Info Kit Now!
Get your next web design project done with our los angeles web design team - Best web design with great price.
Baldwin Linguas:
Translations Interpreting Localization:
English French Portuguese Spanish
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives
EMAIL
PRINT
RSS
SHARE
